Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Atogepant

FDA-approved product (tablet, oral), marketed as Qulipta.

Registered studies
36
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Atogepant
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Migraine disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Calcitonin gene-related peptide (cgrp) antagonists
FDA pharmacologic class
Calcitonin Gene-related Peptide Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

36registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Atogepant in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-2.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Atogepant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effect of Atogepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With Migraine

    NCT07826910 · start 2027-01-01

    Registered record
    Registry ID
    NCT07826910
    Conditions
    Migraine Disorders, Brain; Healthy Adult Participants; Vestibulo-Ocular Reflex
    Interventions
    Atogepant 60 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2027-01-01
    Completion
    2028-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorders, Brain; Healthy Adult Participants; Vestibulo-Ocular Reflex
    InterventionAtogepant 60 mg; Placebo
    PhasePhase 4
    Registry statusNot yet recruiting

  • Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United Kingdom

    NCT07690215 · start 2026-09-01

    Registered record
    Registry ID
    NCT07690215
    Conditions
    Migraine
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2028-03
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)

    NCT07655440 · start 2026-07

    Registered record
    Registry ID
    NCT07655440
    Conditions
    Migraine Associated Vertigo; Tinnitus; Migraine; Vestibular Migraine
    Interventions
    Galcanezumab; Erenumab 70 mg; Eptinezumab; Atogepant; Amitriptyline; Nortriptyline; propranolol; Verapamil SR 120 mg; Candesartan; topiramate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-07
    Completion
    2031-07
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Associated Vertigo; Tinnitus; Migraine; Vestibular Migraine
    InterventionGalcanezumab; Erenumab 70 mg; Eptinezumab; Atogepant +6 more
    PhasePhase 4
    Registry statusNot yet recruiting

  • Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

    NCT06972056 · start 2025-07-09

    Registered record
    Registry ID
    NCT06972056
    Conditions
    Migraine
    Interventions
    Atogepant 60 mg; Propranolol 160 mg; Topiramate 100 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-07-09
    Completion
    2029-12-01
    Enrolment
    1,335

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionAtogepant 60 mg; Propranolol 160 mg; Topiramate 100 mg
    PhasePhase 4
    Registry statusRecruiting

  • A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

    NCT06810505 · start 2025-02-13

    Registered record
    Registry ID
    NCT06810505
    Conditions
    Chronic Migraine
    Interventions
    Atogepant; Placebo for Atogepant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-02-13
    Completion
    2031-03
    Enrolment
    420

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Migraine
    InterventionAtogepant; Placebo for Atogepant
    PhasePhase 3
    Registry statusRecruiting

  • Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

    NCT06806293 · start 2025-02-10

    Registered record
    Registry ID
    NCT06806293
    Conditions
    Menstrual Migraine (MM)
    Interventions
    Atogepant; Placebo for Atogepant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2025-02-10
    Completion
    2027-07
    Enrolment
    468

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenstrual Migraine (MM)
    InterventionAtogepant; Placebo for Atogepant
    PhasePhase 3
    Registry statusActive not recruiting

  • Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine

    NCT06882122 · start 2024-12-01

    Registered record
    Registry ID
    NCT06882122
    Conditions
    Migraine Disorder; Episodic Migraine
    Interventions
    Atogepant 60 mg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-12-01
    Completion
    2026-04
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Disorder; Episodic Migraine
    InterventionAtogepant 60 mg
    PhaseNot recorded
    Registry statusRecruiting

  • Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

    NCT06543914 · start 2024-11-26

    Registered record
    Registry ID
    NCT06543914
    Conditions
    Migraine
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2024-11-26
    Completion
    2029-02
    Enrolment
    1,314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionNot recorded
    PhaseNot recorded
    Registry statusActive not recruiting

  • Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine

    NCT06603558 · start 2024-09-24

    Registered record
    Registry ID
    NCT06603558
    Conditions
    Chronic Migraine; Episodic Migraine; Migraine
    Interventions
    Atogepant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-09-24
    Completion
    2029-05
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Migraine; Episodic Migraine; Migraine
    InterventionAtogepant
    PhaseNot recorded
    Registry statusRecruiting

  • Long-term Atogepant in Real-world Practice

    NCT07699549 · start 2024-06-01

    Registered record
    Registry ID
    NCT07699549
    Conditions
    Migraine; Headache; Headache (Migraine); Migraine Disease; Migraine Disorder; Migraine Headache; Migraine Disability
    Interventions
    Atogepant 60 mg; Headache diary; Patient-reported outcome measures
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-06-01
    Completion
    2026-03-01
    Enrolment
    513

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Headache; Headache (Migraine); Migraine Disease +3 more
    InterventionAtogepant 60 mg; Headache diary; Patient-reported outcome measures
    PhaseNot recorded
    Registry statusCompleted

  • Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients

    NCT06414044 · start 2024-05-09

    Registered record
    Registry ID
    NCT06414044
    Conditions
    Migraine; Migraine With Aura; Migraine Without Aura; Chronic Migraine
    Interventions
    Atogepant 60 mg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2024-05-09
    Completion
    2026-04
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Migraine With Aura; Migraine Without Aura; Chronic Migraine
    InterventionAtogepant 60 mg
    PhaseNot recorded
    Registry statusActive not recruiting

  • Atogepant in Real Life in Italy (GIANT)

    NCT06136442 · start 2024-04-09

    Registered record
    Registry ID
    NCT06136442
    Conditions
    Migraine, Prophylaxis
    Interventions
    Atogepant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-04-09
    Completion
    2024-12-31
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine, Prophylaxis
    InterventionAtogepant
    PhaseNot recorded
    Registry statusUnknown

  • Migraine Medication Effects on Urinary Symptoms

    NCT06212661 · start 2024-04-05

    Registered record
    Registry ID
    NCT06212661
    Conditions
    Overactive Bladder; Bladder Pain Syndrome; Migraine Disorders; Overactive Bladder Syndrome; Overactive Detrusor; Migraine; Interstitial Cystitis
    Interventions
    Ubrogepant; Rimegepant; Atogepant; Eptinezumab; Fremanezumab; Galcanezumab; Erenumab; Botulinum toxin A
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Enrolling by invitation
    Start
    2024-04-05
    Completion
    2026-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder; Bladder Pain Syndrome; Migraine Disorders; Overactive Bladder Syndrome +3 more
    InterventionUbrogepant; Rimegepant; Atogepant; Eptinezumab +4 more
    PhaseNot recorded
    Registry statusEnrolling by invitation

  • Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

    NCT06241313 · start 2024-03-25

    Registered record
    Registry ID
    NCT06241313
    Conditions
    Migraine
    Interventions
    Atogepant; Placebo for Atogepant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2024-03-25
    Completion
    2026-08-11
    Enrolment
    2,158

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionAtogepant; Placebo for Atogepant
    PhasePhase 3
    Registry statusCompleted

  • Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

    NCT07159750 · start 2024-01-02

    Registered record
    Registry ID
    NCT07159750
    Conditions
    Migraine; Episodic Migraine; Chronic Migraine, Headache
    Interventions
    CGRP antibody or gepant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-01-02
    Completion
    2026-01
    Enrolment
    700

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine; Episodic Migraine; Chronic Migraine, Headache
    InterventionCGRP antibody or gepant
    PhaseNot recorded
    Registry statusRecruiting